Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — Investor Presentation (February 2024)
28 slides from Imricor Medical Systems's investor presentation, Feb 2, 2024
Slide 1: Capital Raising Presentation
For personal use only Capital Raising Presentation 2 February 2024 IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Imricor Medical Systems, Inc. (IMR or Imricor) in objectives, financial position or needs of any particular investor. Investors or potential investors connection with IMR’s proposed capital raising (the Capital Raise), comprising: should seek indepen
Slide 3: Disclaimer
Disclaimer Any such statements, opinions and estimates in this presentation speak only as of the date of this product disclosure statement or other offering document under Australian law or any other law presentation, and are based on assumptions and contingencies subject to change without notice, (
Slide 4: Disclaimer
Disclaimer Neither Morgans Corporate Limited (ACN 010 539 607) (the Lead Manager), nor any of their or document. IMR’s respective advisers nor any of their respective affiliates or related bodies corporate, nor any of their respective directors, officers, partners, employees or agents (together, the
Slide 5: Moving cardiac ablation into MRI
Moving cardiac ablation into MRI Conventional x-ray EP lab iCMR EP lab (interventional cardiac magnetic resonance) For personal use only X-ray to iCMR Everyone else Only Imricor Enabled by Imricor’s Physicians, Patients, Hospitals Imricor MRI-compatible devices • Same kinds of tools, same procedures
Slide 6: NorthStar 3D mapping system – the central hub of an iCMR lab
NorthStar 3D mapping system – the central hub of an iCMR lab For personal use only NorthStar brings all iCMR technology together in one place • It controls the MRI • It receives MR images in real time • It displays everything in 3D • It tracks Imricor catheters • It facilitates electroanatomical map
Slide 7: Imricor Summary
Imricor Summary Imricor makes MRI compatible catheters and systems that uniquely enable cardiac ablation procedures to use real-time 3D MRI imaging throughout the procedure. For personal use only Goals of MRI imaging during ablation procedures: Corporate Highlights Share Price Chart1 • Quickly ident
Slide 8: Imricor Leadership
Imricor Leadership Management Board of Directors For personal use only Steve Wedan Jonathon Gut Gregg Stenzel Jennifer Weisz President and Chief Vice President of Chief Operating Vice President of Executive Officer, Finance and Chief Officer Regulatory and Steve Wedan Mark Tibbles and Board Chair Fi
Slide 9: A strong intellectual property portfolio
A strong intellectual property portfolio Imricor’s patents protect technology that For personal use only allows Imricor to manufacture medical devices that are uniquely MRI compatible. Imricor’s IP is relatively new, with the Company’s oldest issued patent expiring 19 issued U.S in 2030 Patents In a
Slide 10: US$8 billion worldwide market
US$8 billion worldwide market1 Drivers of Global Catheter Cardiac Ablation Disposables Market: Ablation Market US, EU, ANZ For personal use only CATHETER SALES (USD M) $9,000.00 Increased incidence of cardiac disease $8,000.00 $7,000.00 $6,000.00 Shift towards $5,000.00 minimally invasive $4,000.00
Slide 11: Wide Geographical Spread
Wide Geographical Spread Imricor are approved for sale in over 30 countries, with 7 countries containing customer sites today For personal use only • Imricor’s products are currently approved in 31 countries, with a further 7 countries with activated live sites • Estimated over 1,000,000 ablation pr
Slide 12: Company timeline
Company timeline 2006 • Imricor is established 2019 • Listed on ASX (ASX: IMR) For personal use only 2007 • Licensed IP from 2020 • Received CE mark approval for Vision-MR Ablation Catheter Johns Hopkins & Vision-MR Dispersive Electrode University 2015 • Signed joint research agreement with Siemens
Slide 13: Company timeline
Company timeline 2022 • Re-launch post-COVID • Joint venture to bring AI into NorthStar COMPLETE • Signed distributor in Saudi Arabia For personal use only 2023 • Approval to start clinical trial for FDA in • Australia & New Zealand US launch • Additional Middle East country launches • Approval to s
Slide 14: Looking forward
Looking forward Imricor’s mission is to establish a new standard of care for cardiac ablations with real- time iCMR guidance. Cardiac ablation is a US$8 billion1 worldwide market For personal use only Primary Drivers of Value • Develop European Market by activating new sites and increasing utilisati
Slide 15: Three areas of focus
Three areas of focus For personal use only 1 2 3 FDA Approval Expand Treatments Commercialisation VISABL-AFL Trial VISABL-VT Trial • Opens largest market in • Demonstrates complex • Activating sites in EU the world ablation in MRI • Grow installed base • Streamlined regulatory • Signals to market •
Slide 16: Pioneer Capital Fund
Pioneer Capital Fund Imricor received a Letter of Intent to Invest from North Dakota’s Pioneer Capital Fund. For personal use only Investment is related to an overall strategy to expand Imricor’s manufacturing operations into North Dakota. Letter of Intent to Invest • US$8 million • Target price of
Slide 17: Investment Highlights
Investment Highlights The world’s first and only For personal use only Founder-led business with deep med-tech experienced commercially available MRI management team compatible ablation catheter Large addressable market, Strong IP portfolio estimated to be US$8bn1 in and patent protection What are t
Slide 18: Capital Raising
For personal use only Capital Raising
Slide 19: Capital Raising Overview
Capital Raising Overview Institutional Placement and Entitlement Offer to raise ~A$15.0 million at A$0.45 per new CDI. • Institutional Placement, US Placement and a 1 for 7.5 Non-Renounceable Entitlement Offer to raise approximately A$15.0 million For personal use only Offer Structure and Size (“Off
Slide 20: Sources and Use of Funds
Sources and Use of Funds Funds raised will be used to fund sales andmarketing, clinical and regulatory development, payment of creditors, offer costs and other working capital. For personal use only Sources1 A$m Uses A$m Capital Raising 15.0 Sales and marketing 2.2 Current Cash at Bank 1.2 Developme
Slide 21: Timetable
Timetable For personal use only Event Date1 Entitlement Offer announced to ASX Friday, 2 February 2024 Announcement of Institutional Entitlement Offer results; voluntary suspension lifted Monday, 5 February 2024 Record date for Retail Entitlement Offer 7:00pm on Tuesday, 6 February 2024 Retail Entit
Slide 22: Risk Factors
Risk Factors For personal use only Imricor will, subject to regulatory clearances, seek to sell its key products in the European Union, the U.S. and Australia. Imricor is not assured of receiving future regulatory clearances and approvals for other indications or in other jurisdictions, and cannot p
Slide 23: Risk Factors
Risk Factors For personal use only The proceeds of the Entitlement Offer will be primarily used to support the commercial launch of the Company’s products in the European Union, Middle East, and ANZ, as well and funding the FDA clinical trial and VT clinical trial in Europe. Imricor may decide to us
Slide 24: Risk Factors
Risk Factors Imricor does not believe that its activities infringe any third party’s intellectual property rights. However, in the future the Company may be subjected to infringement For personal use only claims or litigation arising out of patents and pending applications of its competitors, or thi
Slide 25: Risk Factors
Risk Factors For personal use only As a Delaware company with an ASX listing and a registration as a foreign company in Australia, Imricor will need to ensure it maintains compliance with Delaware law and relevant Australian laws and regulations, including the Listing Rules and certain provisions of
Slide 26: International Offer Restrictions
International Offer Restrictions For personal use only No action has been taken to register the securities or otherwise permit a public offering of securities in any jurisdiction. The distribution of this document outside Australia may be restricted by law. Persons who come into possession of this d
Slide 27: International Offer Restrictions
International Offer Restrictions For personal use only Hong Kong WARNING: This document has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures C
Slide 28: Contact Information
Contact Information For personal use only Investors & Australian Media: Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com Rest of World Media: Nick Twohy Vice President, Marketing and
Imricor Medical Systems — Investor Presentation (February 2024) on 6ix